RxDoctor Payments Data

Antonela Svetic, MD

Neurology · Beavercreek, OHNPI 1245309384

Payments from drug & device makers

$296,599in general payments, 2019–2025

Across 606 payments — averaging $489.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$270K
  • Lexicon Pharmaceuticals, Inc.$22K
  • Pfizer$696
  • Biohaven Pharmaceutical Holding Company Ltd.$502
  • Biohaven Pharmaceuticals, Inc.$397
  • Eisai Inc.$334
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$471%
  • Food & beverage$6,06697%
  • Education$1102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$296,599 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$150,547
Medicare patients
278
Services billed
1,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5026$788,529
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5028$287,864
Nurtec OdtRimegepant Sulfate76$140,786
BotoxOnabotulinumtoxina72$91,475
UbrelvyUbrogepant47$84,611
FingolimodFingolimod Hcl12$84,048
QuliptaAtogepant25$58,183
Emgality PenGalcanezumab-Gnlm48$41,031
SavellaMilnacipran Hcl13$9,790
Duloxetine Hcl281$8,837
Pregabalin163$6,467
Pyridostigmine Bromide37$6,250
Memantine Hcl177$5,282
Propranolol Hcl ErPropranolol Hcl45$2,873
Carbidopa-LevodopaCarbidopa/Levodopa103$2,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$34$287,86428 claims
AbbVieBotox, Ubrelvy, Qulipta, Savella$269,584$244,059157 claims
PfizerNurtec Odt$696$140,78676 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$69$6,25037 claims
Upsher-smith Laboratories LLCTopiramate$23$1,41880 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Beavercreek

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →